Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis

被引:170
作者
Zantl, N
Uebe, A
Neumann, B
Wagner, H
Siewert, JR
Holzmann, B
Heidecke, CD
Pfeffer, K
机构
[1] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, D-81675 Munich, Germany
关键词
D O I
10.1128/IAI.66.5.2300-2309.1998
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite considerable progress, peritonitis and sepsis remain life-threatening conditions. To improve the understanding of the pathophysiology encountered in sepsis, a new standardized and highly reproducible murine model of abdominal sepsis termed colon ascendens stent peritonitis (CASP) was developed. In GASP, a stent is inserted into the ascending colon, which generates a septic focus. GASP employing a stent of 14-gauge diameter (14G stent) results in a mortality of 100% within 18 to 48 h after surgery. By inserting stents of small diameters, mortality can be exactly controlled, Thus, CASP surgery with insertion of a 22G or 18G stent (22G or 18G CASP surgery) results ire 38 or 68% mortality, respectively, 14G GASP surgery leads to a rapid invasion of bacteria into the peritoneum and the blood. as a consequence, endotoxemia occurs, inflammatory cells are recruited, and a systemic inflammatory response syndrome develops. Interestingly, the most pronounced upregulation of inflammatory cytokines (gamma interferon [IFN-gamma], tumor necrosis factor alpha [TNF-alpha] and interleukin-12) is observed in spleen and lungs, GASP surgery followed by stent removal at specific time intervals revealed that all animals survived if intervention was performed after 3 h, whereas removal of the septic focus after 9 h did not prevent death, suggesting induction of autonomous mechanisms of a lethal inflammatory response syndrome, 18G CASP surgery in IFN-gamma receptor-deficient (IFN gamma R-/-) mice revealed an essential role of IFN-gamma in survival of sepsis, whereas TNF receptor p55-deficient (TNFRp55(-/-)) mice did not show altered survival rates. In summary, this study describes a novel animal model that closely mimics human sepsis and appears to be highly suitable for the study; of the pathophysiology of abdominal sepsis. Importantly, this model demonstrates a protective role of IFN-gamma in survival of bacterial sepsis.
引用
收藏
页码:2300 / 2309
页数:10
相关论文
共 63 条
  • [21] THE COMPLEX PATTERN OF CYTOKINES IN SEPSIS - ASSOCIATION BETWEEN PROSTAGLANDINS, CACHECTIN, AND INTERLEUKINS
    ERTEL, W
    MORRISON, MH
    WANG, P
    BA, ZF
    AYALA, A
    CHAUDRY, IH
    [J]. ANNALS OF SURGERY, 1991, 214 (02) : 141 - 148
  • [22] ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
  • [23] INTERLEUKIN-1 RECEPTOR BLOCKADE IMPROVES SURVIVAL AND HEMODYNAMIC PERFORMANCE IN ESCHERICHIA-COLI SEPTIC SHOCK, BUT FAILS TO ALTER HOST RESPONSES TO SUBLETHAL ENDOTOXEMIA
    FISCHER, E
    MARANO, MA
    VANZEE, KJ
    ROCK, CS
    HAWES, AS
    THOMPSON, WA
    DEFORGE, L
    KENNEY, JS
    REMICK, DG
    BLOEDOW, DC
    THOMPSON, RC
    LOWRY, SF
    MOLDAWER, LL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) : 1551 - 1557
  • [24] Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
    Fisher, CJ
    Agosti, JM
    Opal, SM
    Lowry, SF
    Balk, RA
    Sadoff, JC
    Abraham, E
    Schein, RMH
    Benjamin, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1697 - 1702
  • [25] RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISHER, CJ
    DHAINAUT, JFA
    OPAL, SM
    PRIBBLE, JP
    BALK, RA
    SLOTMAN, GJ
    IBERTI, TJ
    RACKOW, EC
    SHAPIRO, MJ
    GREENMAN, RL
    REINES, HD
    SHELLY, MP
    THOMPSON, BW
    LABRECQUE, JF
    CATALANO, MA
    KNAUS, WA
    SADOFF, JC
    ASTIZ, M
    CARPATI, C
    BONE, RC
    FREIDMAN, B
    MURE, AJ
    BRATHWAITE, C
    SHAPIRO, E
    MELHORN, L
    TAYLOR, R
    KEEGAN, M
    OBRIEN, J
    SCHEIN, R
    PENA, M
    WASSERLOUF, M
    OROPELLO, J
    BENJAMIN, E
    DELGUIDICE, R
    EMMANUEL, G
    LIE, T
    ANDERSON, L
    MARSHALL, J
    DEMAJO, W
    ROTSTEIN, O
    FOSTER, D
    ABRAHAM, E
    MIDDLETON, H
    PERRY, C
    LEVY, H
    FRY, DE
    SIMPSON, SQ
    CROWELL, RE
    NEIDHART, M
    STEVENS, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1836 - 1843
  • [26] INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL
    FISHER, CJ
    SLOTMAN, GJ
    OPAL, SM
    PRIBBLE, JP
    BONE, RC
    EMMANUEL, G
    NG, D
    BLOEDOW, DC
    CATALANO, MA
    FRIEDMAN, B
    MURE, A
    SHAPIRO, E
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (01) : 12 - 21
  • [27] TUMOR-NECROSIS-FACTOR-ALPHA IS REQUIRED IN THE PROTECTIVE IMMUNE-RESPONSE AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE
    FLYNN, JL
    GOLDSTEIN, MM
    CHAN, J
    TRIEBOLD, KJ
    PFEFFER, K
    LOWENSTEIN, CJ
    SCHREIBER, R
    MAK, TW
    BLOOM, BR
    [J]. IMMUNITY, 1995, 2 (06) : 561 - 572
  • [28] A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS
    GREENMAN, RL
    SCHEIN, RMH
    MARTIN, MA
    WENZEL, RP
    MACINTYRE, NR
    EMMANUEL, G
    CHMEL, H
    KOHLER, RB
    MCCARTHY, M
    PLOUFFE, J
    RUSSELL, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08): : 1097 - 1102
  • [29] INTERFERON-GAMMA, A MEDIATOR OF LETHAL LIPOPOLYSACCHARIDE-INDUCED SHWARTZMAN-LIKE SHOCK REACTIONS IN MICE
    HEREMANS, H
    VANDAMME, J
    DILLEN, C
    DIJKMANS, R
    BILLIAU, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (06) : 1853 - 1869
  • [30] HOLZHEIMER RG, 1995, ARCH SURG-CHICAGO, V130, P1314